<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05090813</url>
  </required_header>
  <id_info>
    <org_study_id>EMON-201-CHEY</org_study_id>
    <nct_id>NCT05090813</nct_id>
  </id_info>
  <brief_title>A Real-World Study in China for the TECNIS Eyhance™ Intraocular Lens</brief_title>
  <official_title>A Real-World Study Evaluating Clinical Outcomes in China for the TECNIS Eyhance™ Intraocular Lens Model ICB00</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Surgical Vision, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Surgical Vision, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective and retrospective, single-center, single-arm, open-label clinical study&#xD;
      of the TECNIS Eyhance™ IOL. The study will enroll up to 100 subjects from a single site in&#xD;
      China. All subjects will be followed for 12 months postoperatively.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 5, 2021</start_date>
  <completion_date type="Anticipated">January 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mean monocular postoperative DCIVA</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>percentage of eyes that achieve 0.3 ,0.2, 0.1 and 0.0 logMAR monocular DCIVA</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cataracts</condition>
  <arm_group>
    <arm_group_label>TECNIS Eyhance IOL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Model ICB00</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Model ICB00</intervention_name>
    <description>Investigational intraocular lens replaces the natural lens removed during cataract surgery in one or both eyes.</description>
    <arm_group_label>TECNIS Eyhance IOL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients at least 22 years of age&#xD;
&#xD;
          2. Have/had a cataract in one or both eyes, with planned phacoemulsification with&#xD;
             intraocular lens implantation or a history of implantation with TECNIS Eyhance&#xD;
             intraocular lens&#xD;
&#xD;
          3. Availability, willingness and sufficient cognitive awareness to understand the purpose&#xD;
             of the examination procedures and comply with study visits&#xD;
&#xD;
          4. Voluntary participation indicated by the study informed consent form (ICF) signed by&#xD;
             the patient or legal guardian.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Concurrent participation or participation in any other clinical study within 30 days&#xD;
             prior to the preoperative visit&#xD;
&#xD;
          2. Planned monovision correction (one eye designated for near correction).&#xD;
&#xD;
          3. Any other systemic or ocular disease that, in the opinion of the investigator, may&#xD;
             affect the patient's eligibility for the study, affect visual acuity or may require&#xD;
             surgical intervention during the course of the study (e.g., macular degeneration,&#xD;
             cystoid macular edema, diabetic retinopathy, etc.).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnson &amp; Johnson Surgical Vision Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Surgical Vision</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>+1 904-625-3365</phone>
    <email>AANDERS1@its.jnj.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Boao Super Hospital No. 6</name>
      <address>
        <city>Qionghai</city>
        <state>Hainan</state>
        <zip>571434</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hainan Eye Optometry Eye Hospital Co., Ltd. No. 6</name>
      <address>
        <city>Qionghai</city>
        <state>Hainan</state>
        <zip>571434</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 12, 2021</study_first_submitted>
  <study_first_submitted_qc>October 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Johnson &amp; Johnson Medical Devices Companies have an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA project site at http://yoda.yale.edu</ipd_description>
    <ipd_url>http://yoda.yale.edu</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

